p38 mitogen-activated protein kinase as a target for drug discovery

Drugs of the Future

Volumn 24, Issue 12, 1999, Pages 1345-1354

  Henry, James R ^a,b   Cavender, Druie E ^a   Wadsworth, Scott A ^a  

^a Drug Discovery Raritan   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 FLUOROPHENYL) 5 (4 METHYLSULFINYLPHENYL) 3 (4 PYRIDYL)PYRROLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; 5 (2 AMINO 4 PYRIMIDINYL) 4 (4 FLUOROPHENYL) 1 (4 PIPERIDINYL)IMIDAZOLE; 6 (4 FLUOROPHENYL) 2,3 DIHYDRO 5 (4 PYRIDYL)IMIDAZO[2,1 B]THIAZOLE; 6 AMINO 2 (4 FLUOROPHENYL) 4 METHOXY 3 (4 PYRIDYL) 1H PYRROLO[2,3 B]PYRIDINE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DRUG ACTIVITY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; HUMAN; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 0033397562     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.12.858635     Document Type: Review

References (95)

1. Han, J., Lee, J-D., Tobias, P.S., Ulevitch, R.J. Endotoxin induces rapid protein tyrosine phosphorylation in 70Z/3 cells expressing CD14. J Biol Chem 1993, 268: 25009-14.
2. Lee, J.C., Laydon, J.T., McDonnell, P.C. et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372: 739-46.
3. Dinarello, C.A. Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune disease. Curr Opin Immunol 1991, 3: 941-8.
4. Beutler, B.A. The role of tumor necrosis factor in health and disease. J Rheumatol 1999, 26: 16-21.
5. New, L., Han, J. The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 1998, 8: 220-8.
6. Marshall, L.A., Hansbury, M.J., Bolognese, B.J., Gum, R.J., Young, P.R., Mayer, R.J. Inhibitors of the p38 mitogen-activated kinase modulate IL-4 induction of low affinity IgE receptor (CD23) in human monocytes. J Immunol 1998, 161: 6005-13.
7. Lee, J.C., Kassis, S., Kumar, S., Badger, A., Adams, J.L p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials. Pharmacol Ther 1999, 82: 389-97.
8. Wang, X.S., Diener, K., Manthey, C.L. et al. Molecular cloning and characterization of a novel p38 mitogen-activated protein kinase. J Biol Chem 1997, 272: 23668-74.
9. Raingeaud, J., Whitmarsh, A.J., Barrett, T., Derijard, B., Davis, R.J. MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996, 16: 1247-55.
10. Cuenda, A., Rouse, J., Doza, Y.N. et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995, 364: 229-33.
11. Rouse, J., Cohen, P., Trigon, S. et al. A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. Cell 1994, 78: 1027-37.
12. Raingeaud, J., Gupta, S., Rogers, J.S. et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270: 7420-6.
13. Kanakaraj, P., Schafer, P.M., Cavender, D.E. et al. Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production. J Exp Med 1998, 187: 2073-9.
14. Salmon, R.A., Foltz, I.N., Young, P.R., Schrader, J.W. The p38 mitogen-activated protein kinase is activated by ligation of the T or B lymphocyte antigen receptors, Fas or CD40, but suppression of kinase activity does not inhibit apoptosis induced by antigen receptors. J Immunol 1997, 159: 5309-17.
15. Matsuda, S., Moriguchi, T., Koyasu, S., Nishida, E. T lymphocyte activation signals for interleukin-2 production involve activation of MKK6-p38 and MKK7-SAPK/JNK signaling pathways sensitive to cyclosporin A. J Biol Chem 1998, 273: 12378-82.
16. Schafer, P.H., Wang, L., Wadsworth, S.A., Davis, J.E., Siekierka, J.J. T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-α production in a manner distinct from LPS activation of monocytes. J Immunol 1999, 162: 659-68.
17. Schafer, P.H., Wadsworth, S.A., Wang, L., Siekierka, J.J. p38-α mitogen-activated protein kinase is activated by CD28-mediated signaling and is required for IL-4 production by human CD4+CD45R+ T cells and Th2 effector cells. J Immunol 1999, 162: 7110-9.
18. Graves, J.D., Draves, K.E., Craxton, A., Saklatvala, J., Krebs, E.G., Clark, E.A. Involvement of stress-activated protein kinase and p38 mitogen-activated protein kinase in mlgM-induced apoptosis of human B lymphocytes. Proc Natl Acad Sci USA 1996, 93: 13814-8.
19. Tooze, R.M., Doody, G.M., Fearon, D.T. Counterregulation by the coreceptors CD19 and CD22 of MAP kinase activation by membrane immunoglobulin. Immunity 1997, 7: 59-67.
20. Tong, L., Pav, S., White, D.M. et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 1997, 4: 311-6.
21. Baldassare, J.J., Bi, Y., Bellone, C.J. The role of p38 mitogen-activated protein kinase in IL-1-β transcription. J Immunol 1999, 162: 5367-73.
22. Rincon, M., Enslen, H., Raingeaud, J. et al. Interferon-γ expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998, 17: 2817-29.
23. Badger, A.M., Cook, M.N., Lark, M.W. et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J Immunol 1998, 161: 467-73.
24. Sano, Y., Harada, J., Tashiro, S., Gotoh-Mandeville, R., Maekawa, T., Ishii, S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling. J Biol Chem 1999, 274: 8949-57.
25. Lu, H-T., Yang, D.D., Wysk, M. et al. Defective IL-12 production in mitogen-activated protein (MAP) kinase kinase 3 (Mkk3)-deficient mice. EMBO J 1999, 18: 1845-57.
26. Koprak, S., Staruch, M.J., Dumont, F.J. A specific inhibitor of the p38 mitogen activated protein kinase affects differentially the production of various cytokines by activated human T cells: Dependence on CD28 signaling and preferential inhibition of IL-10 production. Cell Immunol 1999, 192: 87-95.
27. Cohen, P.S., Schmidtmayerova, H., Dennis, J. et al. The critical role of p38 MAP kinase in T cell HIV-1 replication. Mol Med 1997, 3: 339-46.
28. Shapiro, L., Heidenreich, K.A., Meintzer, M.K., Dinarello, C.A. Role of p38 mitogen-activated protein kinase in HIV type 1 production in vitro. Proc Natl Acad Sci USA 1998, 95: 7422-6.
29. Ma, X.L., Kumar, S., Feng, G. et al. Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation 1999, 99: 1685-91.
30. Cain, B.S., Meldrum, D.R., Meng, X. et al. p38 MAPK inhibition decreases TNF-α production and enhances postischemic human myocardial function. J Surg Res 1999, 83: 7-12.
31. Nilsson, L., Rogers, J., Potter, H. The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. Front Biosci 1998, 3: D436-46.
32. Hensley, K., Floyd, R.A., Zeng, N-Y. et al. p38 kinase is activated in the Alzheimer's disease brain. J Neurochem 1999, 72: 2053-8.
33. McDonald, D.R., Bamberger, M.E., Combs, C.K., Landret, G.E. β-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci 1998, 18: 4451-60.
34. Pyo, H., Jou, I., Jung, S., Hong, S., Joe, E-H. Mitogen-activated protein kinases activated by lipopolysaccharide and β-amyloid in cultured rat microglia. NeuroReport 1998, 9: 871-4.
35. Kawasaki, H., Morooka, T., Shimohama, S. et al. Activation and involvement of p38 mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 1997, 272: 18518-21.
36. Xia, Z., Dickens, M., Raingeaud, J., Davis, R.J., Greenberg, M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270: 1326-31.
37. Kummer, J.L., Rao, P.K., Heidenreich, K.A. Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1997, 272: 20490-4.
38. Parameswaran, N., Spielman, W.S., Brooks, D.P., Nambi, P. SB 203580 reverses adrenomedullin's effect on proliferation and apoptosis in cultured mesangial cells. Eur J Pharmacol 1999, 371: 75-82.
39. Schwenger, P., Bellosta, P., Vietor, I., Basilico, C., Skolnik, E.Y., Vilcek, J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997, 94: 2869-73.
40. Brenner, B., Koppenhoefer, U.. Weinstock, C., Linderkamp, O., Lang, F., Gulbins, E. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153. J Biol Chem 1997, 272: 22173-81.
41. Kankaanranta, H., De Souza, P.M., Barnes, P.J., Salmon, M., Giembycz, M.A., Lindsay, M.A. SB 203580, an inhibitor of p38 mitogen-activated protein kinase, enhances constitutive apoptosis of cytokine-deprived human eosinophils. J Pharmacol Exp Ther 1999, 290: 621-8.
42. Nemoto, S., Xiang, J., Huang, S., Lin, A. Induction of apoptosis by SB 202190 through inhibition of p38-β mitogen-activated protein kinase. J Biol Chem 1998, 273: 16415-20.
43. Dean, J.L.E., Brook, M., Clark, A.R., Saklatvala, J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999, 274: 264-9.
44. Eyers, P.A., Craxton, M., Morrice, N., Cohen, P., Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 1998, 5: 321-8.
45. de Laszlo, S.E., Visco, D., Agarwal, L. et al. Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg Med Chem Lett 1998, 8: 2689-94.
46. Borsch-Haubold, A.G., Pasquet, S., Watson, S.P. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998, 273: 28766-72.
47. Hunt, A.E., Lali, F.V., Lord, J.D. et al. Role of interleukin (IL)-2 receptor beta-chain subdomains and She in p38 mitogen-activated protein (MAP) kinase and p54 MAP kinase (stress-activated protein kinase/c-jun N-terminal kinase activation. J Biol Chem 1999, 274: 7591-7.
48. Hall-Jackson, C.A., Goedert, M., Hedge, P., Cohen, P. Effect of SB 203580 on the activity of c-Raf in vitro and in vivo. Oncogene 1999, 18: 2047-54.
49. Callahan, L.F. The burden of rheumatoid arthritis: Facts and figures. J Rheumatol 1998, 25 (Suppl. 53): 8-12.
50. Lipsky, P.E. Rheumatoid arthritis. In: Harrison's Principles of Internal Medicine, 14th Ed. McGraw-Hill 1999, Chapter 313.
51. Cavender, D., Haskard, D., Yu, C.-L. et al. Pathways to chronic inflammation in rheumatoid synovitis. Fed Proc 1987, 46: 113-7.
52. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996, 39: 713-22.
53. Brennan, F.M., Maini, R.N., Feldmann, M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 1998, 20: 133-47.
54. Odeh, M. Role of cytokines in rheumatoid arthritis. Drug News Perspect 1998, 11: 331-41.
55. Brennan, F.M., Chantry, D., Jackson, A., Maini, R.N., Feldmann, M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989 ii: 244-7.
56. Henderson, B., Pettipher, E.R. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor α in the rabbit: Evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol 1989, 75: 306-10.
57. Ghivizzani, S.C., Kang, R., Georgescu, H.I. et al. Constitutive intra-articular expression of human IL-1β following gene transfer to rabbit synovium produces all major pathologies of human rheumatoid arthritis. J Immunol 1997, 159: 3604-12.
58. Keffer, J., Probert, L., Cazlaris, H. et al. Transgenic mice overexpressing human tumor necrosis factor: A predictive genetic model of arthritis. EMBO J 1991, 10: 4025-31.
59. Georgopoulos, S., Plows, D., Kollias, G. Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. J Inflamm 1996, 46: 86-97.
60. Probert, L, Plows, D., Kontogeorgos, G., Kollias, G. The type 1 interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF transgenic mice. Eur J Immunol 1995, 25: 1794-7.
61. Joosten, L.A.B., Helsen, M.M.A., van de Loo, F.A.J., van den Berg, W.B. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using antiTNF-α, anti-IL-α/β, and IL-1Ra. Arthritis Rheum 1996, 39: 797-809.
62. Wooley, P.H., Dutcher, J., Widmer, M.B., Gillis, S. Influence of a recombinant human soluble tumor necrosis factor receptor-Fc fusion protein on type II collagen-induced arthritis in mice. J Immunol 1993, 151: 6602-7.
63. Piguet, P.F., Grau, G.E., Vesin, C., Loetscher, H., Gentz, R., Lesslauer, W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992, 77: 510-4.
64. Thorbecke, G.J., Shah, R., Leu, C.H., Kuruvilla, A.P., Hardison, A.M., Palladino, M.A. Involvement of endogenous tumor necrosis factor α and transforming growth factor-β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992, 89: 7375-9.
65. Bendele, A., McAbee, T., Sennello, G., Frazier, J., Chlipala, E., McCabe, D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: Comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999, 42: 498-506.
66. Le, C.H., Nicolson, A.G., Morales, A., Sewell, K.L. Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene. Arthritis Rheum 1997, 40: 1662-9.
67. Issekutz, A.C., Meager, A., Otterness, I., Issekutz, T.B. The role of tumour necrosis factor-alpha and IL-1 in polymorphonuclear leucocyte and T lymphocyte recruitment to joint inflammation in adjuvant arthritis. Clin Exp Immunol 1994, 97: 26-32.
68. van de Loo, F.A.J., Joosten, L.A.B., van Lent, P.L.E.M., Arntz, O.J., van den Berg, W.B. Role of interleukin-1, tumor necrosis factor α, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Arthritis Rheum 1995, 38: 164-72.
69. Elliott, M.J., Maini, R.N., Feldmann, M. et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344: 1105-10.
70. Rankin, E.C.C., Choy, E.S.H., Kassimos, D. et al. The therapeutic effects of an engineered human anti-tumour necrosis factor a antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995, 34: 334-42.
71. Maini, R.N., Breedveld, F.C., Kalden, J.R. et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor a monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41: 1552-63.
72. van Dullemen, H.M., van Deventer, S.J.H., Hommes, D.W. et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995, 109: 129-35.
73. Stack, W.A., Mann, S.D., Roy, A.J. et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 1997, 349: 521-4.
74. Moreland, L.W., Baumgartner, S.W., Schiff, M.H. et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337: 141-7.
75. Moreland, L.W., Schiff, M.H., Baumgartner, S.W. et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999, 130: 478-86.
76. Moreland, L.W. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999, 26 (Suppl. 57): 7-15.
77. Sorbera, L.A., Rabasseda, X., Leeson, P.A. Etanercept. Drugs Fut 1998, 23: 951-4.
78. Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998, 41: 2196-204.
79. Gabay, C., Arend, W.P. Treatment of rheumatoid arthritis with IL-1 inhibitors. Springer Semin Immunopathol 1998, 20: 229-46.
80. Badger, A.M., Bradbeer, J.N., Votta, B., Lee, J.C., Adams, J.L., Griswold, D.E. Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279: 1453-61.
81. Boehm, J.C., Smietana, J.M., Sorenson, M.E. et al. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency. J Med Chem 1996, 39: 3929-37.
82. Henry, J.R., Rupert, K.C., Dodd, J.H. et al. 6-Amino-2-(4-fluorophenyl)-4-methoxy-3-(4-pyridyl)-1H-pyrrolo[2,3-b]pyridine (RWJ 68354): A potent and selective p38 kinase inhibitor. J Med Chem 1998, 41: 4196-8.
83. Gallagher, T.F., Seibel, G.L., Kassis, S. et al. Regulation of stress-induced cytokine production by pyridinylimidazoles: Inhibition of CSBP kinase. Bioorg Med Chem 1997, 5: 49-64.
84. Wang, Z., Canagarajah, B.J., Boehm, J.C. et al. Structural basis of inhibitor selectivity in MAP kinases. Structure 1998, 6: 1117-28.
85. Liverton, N.J., Butcher, J.W., Claiborne, C.F. et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J Med Chem 1999, 42: 2180-90.
86. Wadsworth, S.A., Cavender, D.E., Beers, S.A. et al. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 1999, 291: 680-7.
87. Henry, J.R., Rupert, K.C., Dodd, J.H. et al. Potent inhibitors of the MAP kinase p38. Bioorg Med Chem Lett 1998, 8: 3335-40.
88. Anon. Substituted pyrazoles as p38 kinase inhibitors. Exp Opin Ther Patents 1999, 9: 975-9.
89. Adams, J.L., Boehm, J.C., Kassis, S. et al. Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg Med Chem Lett 1998, 8: 3111-6.
90. Wilson, K.P., McCaffrey, P.G., Hsiao, K. et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997, 4: 423-31.
91. Young, P.R., McLaughlin, M.M., Kumar, S. et al. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 1997, 272: 12116-21.
92. Lisnock, J., Tebben, A., Frantz, B. et al. Molecular basis for p38 protein kinase inhibitor specificity. Biochemistry 1998, 37: 16573-81.
93. Eyers, P.A., Craxton, M., Morrice, N., Cohen, P., Goedert, M. Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single ammo-acid substitution. Chem Biol 1998, 5: 321-8.
94. Frantz, B., Klatt, T., Pang, M. et al. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyrimidinylimidazole inhibitor binding. Biochemistry 1998, 37: 13846-53.
95. Vertex commences pilot phase II study of VX-745 for rheumatoid arthritis. DailyDrugNews.com (Daily Essentials) Nov 4, 1999.